Similarly, studies have found that the mRNA expression level of interleukins 25 (IL-25) in PBMCs of malignant and benign breast patients was significantly lower than that of non-cancer individuals (P < 0.05), and the decrease of IL-25 was also related to the grading and staging of breast cancer (Barati et al., 2020). This evidence concerns the gene IL25 and breast carcinoma.